Hepatotropic medicines: current status
Limits of administration, efficacy and safety of hepatotropic drugs are not finally formulated yet because of lack of clinical trials which satisfy current principles of evidence-based medicine. The review analyses data on clinical use of drugs for which hepatotropic action is leading, prevalent or...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2012-02-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/31009 |
| _version_ | 1811204460580438016 |
|---|---|
| author | Sergey Vladimirovich Okovityy Dmitriy Sergeevich Sukhanov A Yu Petrov Mikhail Grigor'evich Romantsov S V Okovity D S Sukhanov A Yu Petrov M G Romantsov |
| author_facet | Sergey Vladimirovich Okovityy Dmitriy Sergeevich Sukhanov A Yu Petrov Mikhail Grigor'evich Romantsov S V Okovity D S Sukhanov A Yu Petrov M G Romantsov |
| author_sort | Sergey Vladimirovich Okovityy |
| collection | DOAJ |
| description | Limits of administration, efficacy and safety of hepatotropic drugs are not finally formulated yet because of lack of clinical trials which satisfy current principles of evidence-based medicine. The review analyses data on clinical use of drugs for which hepatotropic action is leading, prevalent or clinically independent; gives information on composition of some drugs, pharmacodynamics, pharmacokinetics, principles of clinical administration, side effects, clinical trials; outlines a mechanism of action and area of application of a new original hepatotropic drug remaxol. Experimental data are available on remaxol ability to reduce hepatic affection induced by hepatotoxic agents and severity of carbohydrate, protein and fat dystrophy, to activate regeneration of the liver. Clinical trials demonstrate remaxol efficacy in management of toxemia, cytolysis, cholestasis. The above effectiveness and its antiasthenic and antidepressive activity makes this drug a universal hepatotropic medicine effective in various hepatic diseases (viral hepatitis C, toxic and pharmacological damage) both in therapeutic and prophylactic schemes. |
| first_indexed | 2024-04-12T03:13:37Z |
| format | Article |
| id | doaj.art-dec295fc5f984825b488cf8c7d5b6bf1 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-04-12T03:13:37Z |
| publishDate | 2012-02-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-dec295fc5f984825b488cf8c7d5b6bf12022-12-22T03:50:16Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422012-02-01842626828025Hepatotropic medicines: current statusSergey Vladimirovich OkovityyDmitriy Sergeevich SukhanovA Yu PetrovMikhail Grigor'evich RomantsovS V Okovity0D S Sukhanov1A Yu PetrovM G Romantsov2S.M. Kirov Military Medical Academy, St-PetersburgI.I. Mechnikov North-west medical university, St-PetersburgI.I. Mechnikov North-west medical university, St-PetersburgLimits of administration, efficacy and safety of hepatotropic drugs are not finally formulated yet because of lack of clinical trials which satisfy current principles of evidence-based medicine. The review analyses data on clinical use of drugs for which hepatotropic action is leading, prevalent or clinically independent; gives information on composition of some drugs, pharmacodynamics, pharmacokinetics, principles of clinical administration, side effects, clinical trials; outlines a mechanism of action and area of application of a new original hepatotropic drug remaxol. Experimental data are available on remaxol ability to reduce hepatic affection induced by hepatotoxic agents and severity of carbohydrate, protein and fat dystrophy, to activate regeneration of the liver. Clinical trials demonstrate remaxol efficacy in management of toxemia, cytolysis, cholestasis. The above effectiveness and its antiasthenic and antidepressive activity makes this drug a universal hepatotropic medicine effective in various hepatic diseases (viral hepatitis C, toxic and pharmacological damage) both in therapeutic and prophylactic schemes.https://ter-arkhiv.ru/0040-3660/article/view/31009hepatotropic medicineshepatic diseasesremaxol |
| spellingShingle | Sergey Vladimirovich Okovityy Dmitriy Sergeevich Sukhanov A Yu Petrov Mikhail Grigor'evich Romantsov S V Okovity D S Sukhanov A Yu Petrov M G Romantsov Hepatotropic medicines: current status Терапевтический архив hepatotropic medicines hepatic diseases remaxol |
| title | Hepatotropic medicines: current status |
| title_full | Hepatotropic medicines: current status |
| title_fullStr | Hepatotropic medicines: current status |
| title_full_unstemmed | Hepatotropic medicines: current status |
| title_short | Hepatotropic medicines: current status |
| title_sort | hepatotropic medicines current status |
| topic | hepatotropic medicines hepatic diseases remaxol |
| url | https://ter-arkhiv.ru/0040-3660/article/view/31009 |
| work_keys_str_mv | AT sergeyvladimirovichokovityy hepatotropicmedicinescurrentstatus AT dmitriysergeevichsukhanov hepatotropicmedicinescurrentstatus AT ayupetrov hepatotropicmedicinescurrentstatus AT mikhailgrigorevichromantsov hepatotropicmedicinescurrentstatus AT svokovity hepatotropicmedicinescurrentstatus AT dssukhanov hepatotropicmedicinescurrentstatus AT ayupetrov hepatotropicmedicinescurrentstatus AT mgromantsov hepatotropicmedicinescurrentstatus |